<DOC>
	<DOC>NCT00658749</DOC>
	<brief_summary>This is a phase one study to evaluate the safety, tolerability, and bioavailability of nebulized AIR645.</brief_summary>
	<brief_title>A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion Criteria*: Good General Health (with or without allergic rhinitis and/or controlled asthma) Nonsmoker for at least 2 years Normal lung function (DLCO) Able to provide informed consent and to understand and comply with the requirements of the study Exclusion Criteria*: Clinically significant medical history or condition which precludes participation Clinically significant ECG abnormality Clinically significant VS or PE abnormality Clinically significant screening lab abnormality Abnormal lung function (FEV1 &lt;80% predicted) Respiratory infection within 14 days of randomization HBV, HCV, or HIV Breastfeeding or pregnant female History of alcohol abuse or illicit drug use within past 24 months Use of any tobacco or nicotinecontaining product within past 6 months Use of any herbal supplement, overthecounter drug, or prescription drug that is not allowed per protocol Use of any investigational drug within past 30 days Use of any investigational monoclonal antibody or recombinant protein within past 90 days Donation of plasma within past 7 days Donation or loss of whole blood within past 56 days Simplified list of I/E criteria; unabridged list available upon request.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>AIR645</keyword>
	<keyword>Altair Therapeutics</keyword>
	<keyword>IL4</keyword>
	<keyword>IL13</keyword>
	<keyword>IL-4</keyword>
	<keyword>IL-13</keyword>
</DOC>